Cancer Nanotechnology


Enhancement of anticancer action of traditional (doxorubicin and cisplatin) and experimental (landomycin A) drugs by their delivery in vivo with novel C60-fullerene-based nanocarriers possessing innate ROS-modulating activity

, , , , , , , , , , , , , ,
Rapid development of multi-drug resistance of tumor cells to chemotherapy caused by the over-expression of specific ABC-transporter proteins and/or multiple defects in genes involved in cell cycle and apoptosis regulation in cancer cells frequently leads [...]

Journal: TechConnect Briefs
Volume: 3, Biotech, Biomaterials and Biomedical: TechConnect Briefs 2017
Published: May 14, 2017
Industry sector: Medical & Biotech
Topics: Biomaterials, Cancer Nanotechnology
ISBN: 978-0-9988782-0-1